L-Carnitine

Resumen del Protocolo

Resumen conciso del once-daily subcutaneous regimen.

• Objetivo:Support mitochondrial fatty acid oxidation and energy metabolism while avoiding TMAO production associated with oral dosing.
• Programa:Inyecciones subcutáneas diarias por 8–12 semanas (extend to 16 semanas if desired).
• Rango de dosis:50–100 mg daily with gradual titration; advanced protocols may use up to 200 mg daily.
• Reconstitución:2.0 mL per 200 mg vial (100 mg/mL) for precise 1:1 unit-to-milligram measurement.
• Almacenamiento:Lyophilized frozen; reconstituted refrigerated; evitar congelar y descongelar repetidamente.

Protocolo de Dosis

Enfoque de dosis diaria sugerido based on clinical literature.

• Inicio:50 mg diarias durante Semanas 1–2 para evaluar tolerancia and monitor for inyectarion-site reactions.
• Mantenimiento:Aumentar to 100 mg daily from Semana 3 onward; this is a reasonable dosis de mantenimiento for most research purposes.
• Advanced:Up to 200 mg diarias durante robust experimental protocols, if clearly supported by research findings.
• Frecuencia:Una vez al día subcutáneamente (any consistent time; morning or pre-exercise commonly used).
• Duración del ciclo:8–12 semanas; optional extension to 16 semanas with continued monitoring.
• Site Rotation:Rotar sitio de inyeccións systematically (abdomen, thighs, upper arms) to prevent tissue irritación.

Pasos para Reconstituir

• Extraer2.0 mLbacteriostatic water (0.9% benzyl alcohol) with a sterile syringe.
• Inyectar slowly down the vial wall to minimize foaming; avoid direct stream onto powder.
• Gently swirl or roll the vial until powder is fully dissolved (do not shake vigorously).
• Label vial with reconstitution date and refrigerate at2–8 °C (35.6–46.4 °F), protegido de la luz.
• Utilizar en un plazo de2–4 semanas; bacteriostatic water preservative inhibits microbial growth during multi-dose use.

Posibles Beneficios

Observations from clinical and preclinical literature on L-Carnitine supplementation.